<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166405">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931489</url>
  </required_header>
  <id_info>
    <org_study_id>217330</org_study_id>
    <secondary_id>FVF4479s</secondary_id>
    <nct_id>NCT00931489</nct_id>
  </id_info>
  <brief_title>Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) - Correlation With Lucentis(R) Therapy</brief_title>
  <acronym>Antibody</acronym>
  <official_title>Retinal and RPE Autoimmunity in AMD: Assessment of Correlation With Degree of Response to Ranibizumab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawrence S. Morse, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope to determine if &quot;wet&quot; AMD patients differ from patients with &quot;dry&quot;
      AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or
      anti-retinal antibody formation. To explain: the immune system can make antibodies that
      attack our own cells, specifically the RPE and the retina. Normally the RPE and retinal
      cells are ignored by the immune system, but when disease occurs, immune reactions can occur,
      making an autoantibody that can attack the patient's own cells and make things worse. This
      production of autoantibodies that react with our own RPE and retinal cells is what the
      investigators want to test in this proposal to see if they may contribute to, or are
      responsible for, a poor response to treatment.

      The investigators also want to know how those patients who initially respond to the
      standard-of-care treatment, ranibizumab injections, differ in the production of anti-RPE or
      anti-retinal antibody formation, from those patients who do not respond initially after 4
      consecutive injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 10% of patients with neovascular AMD treated with ranibizumab respond poorly or worsen
      despite therapy. The reason for this lack of response is unclear. We have preliminary data
      that suggests abnormal autoimmune activity is apparent in these patients. Previous studies
      have shown evidence of retinal autoimmunity in AMD patients, but there is very little data
      describing any specific immunologic commonality that correlates with disease and/or poor
      response. (8,9) Perhaps just as significantly there is little data regarding the immunologic
      activity of age-matched normals, making published data hard to evaluate especially in this
      age group in which autoimmunity is known to increase. (8,9) While there are many known
      retinal antigens in autoimmune retinal disease, the role of these antigens is not well
      established in AMD and not all the antigens have been identified. (24) Moreover,
      RPE-reactivities are only beginning to be understood in ocular disease. (25-27) We intend to
      address humoral responses in AMD by making a systematic comparison of the immunologic
      activity of ranibizumab responders, ranibizumab initial non-responders, and a comparable
      population of age-sex-race matched normal controls. Data suggests that 5 groups of patients
      are evident after 3 treatments with ranibizumab: 1) rapid responders, 2) delayed responders,
      3) gradual responders, 4) acutenon-responders and 5) chronic non-responders. We hypothesize
      that non-responders and gradual responders may in fact be patients with complicating
      underlying autoimmune activity involving retinal and RPE antigens, which are exposed
      secondary to the breakdown of the blood-retinal barrier during CNV development. We will
      study this humoral response (antibody production) over the treatment period, as it likely is
      changing at different rates in the patients with different responses. In addition we will
      correlate underlying genetic phenotype in these patients.

      For this study, we plan to look at 2 treatment groups and 2 control groups:

        -  Group 1: patients with neovascular AMD who respond to ranibizumab after 4 consecutive
           injections with ranibizumab

        -  Group 2: age-sex-race matched normal population controls (without AMD)

        -  Group 3: patients with neovascular AMD who are acute non-responders to anti-VEGF
           treatment after 4 or more consecutive injections

        -  Group 4: age-sex-race matched dry AMD patients (AREDS category 2/3 ou) controls

        -  Group 5: patients with neovascular AMD who are chronic non-responders to anti-VEGF
           treatment after 4 or more consecutive injections

      This is an open-label study assessing antibody formation (anti-RPE and anti-retinal) in 5
      groups. Group 1 (n=40) will include neovascular AMD patients treated with ranibizumab.
      Patients will be included and receive 4 ranibizumab 0.5mg intravitreally at 4-6 week
      intervals and then twice more &quot;as needed&quot; (PRN) at 4-6 week intervals. After the 4th
      ranibizumab injection, if a Group 1 patient has not responded (persistent fluid on OCT),
      they will be moved into Group 3 (anti-VEGF acute non-responders) or Group 5 (anti-VEGF
      chronic non-responders). This will reduce the eventual number of subjects enrolled in Group
      1 to approximately 36, as we anticipate approximately 4 subjects to have to move to either
      Group 3 or Group 5 as a non-responder. Group 2 (n=40) will be an age-sex-race matched normal
      subjects from the population that does not have AMD. Group 3 (n=8) and Group 5 (n=7) (for a
      combined total of 15 subjects, approximately 4 of whom transferred from Group 1) include
      patients treated with 4 or more injections of anti-VEGF treatment at 4-8 week intervals
      without an initial response (Initial non-response is defined as &lt; 100 microns of improved
      [decreased] retinal thickening by OCT). Group 3 patients, the acute non-responders, will be
      included after the 4th injection and followed for 2 more visits at 4-8 week intervals during
      which time they can receive &quot;as needed&quot; anti-VEGF treatment(s) at the investigator's
      discretion for any fluid on OCT. Group 4 (n=40) will be age-sex-race matched patients with
      Dry AMD as controls for immune response before there is a neovascular response. Group 5
      patients, the chronic non-responders, will be included after the 4th injection and followed
      for one (1) visit at Month 4 during which time they can receive an &quot;as needed&quot; anti-VEGF
      treatment at the investigator's discretion for any fluid on OCT.

      NOTE: Only 10% of Group 1 (approximately 4 patients) are expected to be non-responders,
      therefore, 11 of the Group 3 and Group 5 subjects will be patients treated outside the study
      who are found to be non-responders by chart review. These patients will then be enrolled at
      the Month 4 visit to supplement the subjects transferred from Group 1 for a total of 15
      patients in Groups 3 and 5.

      We will use Western blotting for global assessment of all autoantibodies against the full
      complement of retinal proteins in both normal individuals (Group 2) and those treated for
      exudative AMD (Group 1), those initial non-responders to ranibizumab (Group 3), and patients
      with &quot;dry&quot; AMD (Group 4).

      Genotyping (CFH and HTRA1) will be performed on all Groups. Approximately 25 ml (2
      tablespoons) of blood will be sent to Dr. Khang Zhang of the Shiley Eye Center at the
      University of California, San Diego and he will perform the genetics analysis.

      This study will investigate if antibody production differs between nv AMD patients (Groups
      1, 3 and 5) and the normal population (Group 2), if it differs between ranibizumab
      responders (Group 1) and non-responders to any anti-VEGF treatment (Groups 3 and 5), and we
      will also see how patients with dry AMD (Group 4) compare with the nv AMD groups (Groups 1,
      3, and 5).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if &quot;wet&quot; AMD patients (Group 1 and Group 3) differ from population normals (Group 2) in the production of anti-Retinal Pigment Epithelium (RPE) or anti-retinal antibody formation.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine mean change in visual acuity (VA) and ocular coherence tomography (OCCT) from baseline to month 6</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Wet AMD Patients Responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Population</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Dilated eye exam and 3 Tbls. blood draw at first and only study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wet AMD Patients Acute Non-responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dry AMD Population</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Dilated eye exam and 3 Tbls. blood draw at first and only study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wet AMD Patients Chronic Non-responderes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this Group will have not responded to 4 or more prior injections of anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab (Lucentis(R))</intervention_name>
    <description>0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months</description>
    <arm_group_label>Wet AMD Patients Responders</arm_group_label>
    <arm_group_label>Wet AMD Patients Acute Non-responders</arm_group_label>
    <arm_group_label>Wet AMD Patients Chronic Non-responderes</arm_group_label>
    <other_name>Lucentis(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 (Ranibizumab Responders):

               -  Ability to provide written informed consent and comply with study assessments
                  for the full duration of the study

               -  Age &gt; 50 years

               -  Patients with active neovascular &quot;wet&quot; AMD na√Øve to treatment

          -  Group 2 (Normal Controls):

               -  Age-sex-race matched to Group 1 patients

               -  Non-AMD

               -  Ability to provide written informed consent

          -  Group 3 (Anti-VEGF Initial Non-responders):

               -  &quot;Wet&quot; AMD patient treated with 4 or more monthly injections of anti-VEGF
                  treatment without an adequate response (persistent fluid on OCT)

               -  Ability to provide written informed consent and comply with study assessments
                  for the full duration of the study

               -  Age &gt; 50 years

          -  Group 4 (&quot;Dry&quot; AMD):

               -  Age-sex-race matched to Group 1 patients

               -  &quot;Dry&quot; AMD, category 2 or 3 by AREDS (Age-Related Eye Disease Study) criteria

               -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception. The following are considered
             effective means of contraception: surgical sterilization or use of oral
             contraceptives, barrier contraception with either a condom or diaphragm in
             conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Concurrent eye disease in the study eye that could compromise visual acuity (e.g.,
             diabetic retinopathy, advanced glaucoma)

          -  Previous AMD therapy

          -  Patients being treated for autoimmune or other disease with immunomodulatory drugs
             (i.e., prednisone, infliximab, methotrexate)

          -  Patients with recent (less than 6 months) ocular or systemic surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence S Morse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 26, 2014</lastchanged_date>
  <firstreceived_date>June 29, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Lawrence S. Morse, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Retinal and RPE Autoimmunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
